This invention provides a method for improving learning and memory and treating neurological disease associated with auditory, visual, somatosensory or motor abnormalities. The invention involves administration of an inhibitor of ecto-5’-nucleotidase (Nt5e, aka CD73) or A1 adenosine receptor (A1R, aka Adora1). Various molecules and compounds capable of inhibiting these two genes are disclosed.
During the first 2 to 4 years of life, humans learn much more efficiently than they do during adulthood. This ability to learn depends on plastic changes in the cortices of the brain. In adults, this plasticity is lost and the ability to learn is diminished. Researchers at St. Jude discovered that inhibiting adenosine production or signaling in the auditory thalamus, which processes auditory information, can convert adult-like plasticity to juvenile-like plasticity. Thus, by inhibiting the expression or function of Nt5e or A1R, learning abilities in adults can be rejuvenated.
Cortical plasticity, adenosine regulation, improved learning, neurological disease
Granted Patents or Published Applications
Published international patent application 2016/0134091
Related Scientific References
We are currently seeking licensing opportunities in all fields for the development of this technology. If you are interested in commercially developing this invention to treat learning and memory defects and/or neurological diseases associated with an abnormal auditory, visual, or somatosensory perception; or any other use, please contact our office. Contact: email@example.com.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.